Table 3 Clinical trials related to CD8+ T cells
From: The expanding Pandora’s toolbox of CD8+T cell: from transcriptional control to metabolic firing
NCT number | Study title | Study status | Interventions |
|---|---|---|---|
NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+ T Cells in Patients With Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Infusion of iNKT cells and CD8+ T cells |
NCT02424916 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study | COMPLETED | BIOLOGICAL: Melanoma antigens-specific CD8+ T lymphocytes |
NCT04965649 | Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi + Hematological Malignancies | RECRUITING | GENETIC: Phenotyping of total and innate CD8 + T cells by flow cytometry |
NCT03175705 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | UNKNOWN | BIOLOGICAL: HCC antigens-specific CD8+ T lymphocytes|DRUG: IL-2|DRUG: Tegafur |
NCT05902520 | Adoptive Cell Therapy Using Cancer Specific CD8 + Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | RECRUITING | BIOLOGICAL: DP CD8 TIL|BIOLOGICAL: DP CD8 TIL KD|BIOLOGICAL: Low dose IL-2 |
NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous CD8+ SLC45A2-specific T Lymphocytes|DRUG: Cyclophosphamide|BIOLOGICAL: Ipilimumab |
NCT04713046 | Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16 + Cancers | RECRUITING | BIOLOGICAL: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|BIOLOGICAL: Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16 |
NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous CD8 + Melanoma Specific T Cells|DRUG: Cyclophosphamide|BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis |
NCT03450122 | Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma | COMPLETED | BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|DRUG: Cyclophosphamide|BIOLOGICAL: Dendritic Cell-targeting Lentiviral Vector ID-LV305 |
NCT01513408 | Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy | ACTIVE_NOT_RECRUITING | OTHER: immunohistochemical detection of lymphocytes T CD8+ /Foxp3 ratio |
NCT05430555 | A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic MAGE-A1 + Solid Tumors | RECRUITING | BIOLOGICAL: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR |
NCT03338972 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | COMPLETED | BIOLOGICAL: Autologous Anti-BCMA-CAR-expressing CD4+ /CD8+ T-lymphocytes FCARH143|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Leukapheresis |
NCT03747484 | Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | RECRUITING | BIOLOGICAL: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|DRUG: Avelumab|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Interferon Gamma-1b |
NCT02319824 | NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy | COMPLETED | BIOLOGICAL: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|OTHER: Laboratory Biomarker Analysis|RADIATION: Palliative Radiation Therapy |
NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+ /CD8+ T-lymphocytes|DRUG: Cyclophosphamide|DRUG: Fludarabine|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|OTHER: Pharmacological Study |